{"nctId":"NCT01091168","briefTitle":"Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer","startDateStruct":{"date":"2009-07","type":"ACTUAL"},"conditions":["Breast Cancer","Metastases"],"count":594,"armGroups":[{"label":"arm A: Vinflunine","type":"EXPERIMENTAL","interventionNames":["Drug: vinflunine"]},{"label":"arm B: Alkylating agent of physician choice","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Alkylating agent of physician choice registered in cancer"]}],"interventions":[{"name":"vinflunine","otherNames":["JAVLOR","L00070"]},{"name":"Alkylating agent of physician choice registered in cancer","otherNames":["Various"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:(main conditions)\n\n* Female patients 18 to 75 years of age with metastatic breast cancer histologically/cytologically confirmed not amenable to curative surgery or radiotherapy and who have received at least two prior chemotherapy regimens including anthracyclines,taxanes,antimetabolite and vinca-alkaloid and are no longer candidate for these drugs,\n* Karnofsky performance score of at least 70 %, adequate haematological, hepatic and renal functions and ECG without clinically relevant abnormality.\n\nExclusion Criteria:\n\n* Concurrent serious uncontrolled medical disorder,\n* known or clinical evidence of brain metastases or leptomeningeal involvement,\n* pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascites,\n* history of second primary malignancy,\n* HIV infection, preexisting neuropathy,\n* pregnancy or breast feeding.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"The main endpoint of this study is overall survival defined as the time from randomisation to the date of death or last follow-up. For patients who have not died, survival duration will be censored at the date of last contact or last follow-up or the date of last news.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"9.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR)","description":"DCR was defined as the proportion of patients with Complete Response (CR), Partial Response (PR) and stable disease (SD), relative to the total number of patients in the analysed population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.6","spread":null},{"groupId":"OG001","value":"35.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS was defined as the time from randomisation to the first tumour progression or death due to any cause in the absence of previous documentation of objective tumour progression. PFS was performed in the ITT and eligible populations every 6 weeks based on RECIST version 1.1. For patients lost of follow up, or without a known record of progression or death, PFS was censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression which ever occured last.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":82,"n":297},"commonTop":["Nausea","Asthenia","Constipation","Abdominal pain","Stomatitis"]}}}